Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 10, 2025Open Access

Efficacy and Safety of CAR T-cell Therapy in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia: A Systematic Review and Meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

RKRakhshanda KhanSOSai Manohar Raju ObbaniSTSanjana Thota

Discussion

Loading...

Member takes

Overview

Systematic review shows high efficacy of CAR T-cell therapy in relapsed/refractory B-cell ALL, suggesting favorable outcomes with particular co-stimulatory agents.

Key Points

  • CAR T-cell therapy demonstrates a significant remission rate in relapsed/refractory B-cell ALL.
  • The pooled relapse rate was found to be 0.39, with CD19 and CD22 therapies showing no significant difference.
  • The systematic review included data from 32 studies involving over 155,000 patients and used random effects models.
  • This research highlights the potential of CAR T-cell therapy while emphasizing the need for further refinements in treatment approaches.

Cite This Study

Khan et al. (2025) studied this question.

synapsesocial.com/papers/68c23a74b210217d647811e0https://doi.org/10.1101/2025.08.31.25334789
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched one closely related paper. Consider it for comparative context:

  1. 1Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries2021 · 114,173 citations